Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.7.0.1
Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 3 Months Ended
Jan. 09, 2017
Aug. 04, 2016
Feb. 27, 2014
Sep. 30, 2016
Aug. 31, 2016
Jul. 24, 2012
Jun. 15, 2012
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Feb. 16, 2016
Commitments and Contingencies (Textual)                      
Research recorded fees               $ 4,504,351 $ 3,765,452    
Cost of lease agreement         $ 2,400     17,000      
Accounts payable and accrued expenses               4,768,808   $ 4,194,874  
Manufacturing Agreement [Member]                      
Commitments and Contingencies (Textual)                      
Project estimated cost     $ 6,800,000         2,600,000      
Non - refundable institutional fee     $ 600,000                
Total project estimated to cost               100,000   $ 100,000  
Research and development costs               100,000 100,000    
CRO Agreement [Member]                      
Commitments and Contingencies (Textual)                      
Project estimated cost   $ 4,600,000           200,000      
AbbVie Biotherapeutics Corp [Member]                      
Commitments and Contingencies (Textual)                      
Milestones Payments               7,750,000      
AbbVie Biotherapeutics Corp [Member] | Product Development and Patent License Agreement [Member]                      
Commitments and Contingencies (Textual)                      
License fee payment               3,000,000      
Milestones Payments               $ 7,750,000      
Description of royalty payment               The Company shall pay to AbbVie Biotherapeutics Corp. on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.      
Royalty of net sales percentage               12.00%      
First commercial sale period               12 years 6 months      
AbbVie Biotherapeutics Corp [Member] | After first net sales [Member]                      
Commitments and Contingencies (Textual)                      
Milestones Payments               $ 1,500,000      
AbbVie Biotherapeutics Corp [Member] | Phase 1 Clinical Trial of a licensed product [Member]                      
Commitments and Contingencies (Textual)                      
Milestones Payments           $ 750,000   750,000      
Accounts payable and accrued expenses               750,000      
AbbVie Biotherapeutics Corp [Member] | Phase 2 Clinical Trial of a licensed product [Member]                      
Commitments and Contingencies (Textual)                      
Milestones Payments               750,000      
Research and development costs       $ 750,000              
Abbott Biotherapeutics Corp [Member] | After first net sales [Member] | Product Development and Patent License Agreement [Member]                      
Commitments and Contingencies (Textual)                      
Net sales in milestones payment               10,000,000      
Oak Ridge National Laboratory [Member]                      
Commitments and Contingencies (Textual)                      
Research and development costs $ 700,000             $ 100,000 200,000    
Icon Clinical Research [Member]                      
Commitments and Contingencies (Textual)                      
Down payment of project estimated cost percentage               12.50%      
Down payment for project               $ 1,900,000      
Down payment paid in 2007 and 2012               200,000      
Total project estimated to cost               2,700,000      
Research and development costs               0 200,000    
Fred Hutchinson Cancer Research Center [Member] | License and sponsored research agreement [Member]                      
Commitments and Contingencies (Textual)                      
Milestones Payments             $ 1,000,000        
Description of royalty payment             Royalty payments of 2% of net sales will be due to FHCRC.        
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )             $ 200,000        
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )             300,000        
Research recorded fees               27,000 63,000    
Fred Hutchinson Cancer Research Center [Member] | Maximum [Member] | License and sponsored research agreement [Member]                      
Commitments and Contingencies (Textual)                      
Clinical trial cost for approval of food and drug administration             23,500,000        
Fred Hutchinson Cancer Research Center [Member] | Minimum [Member] | License and sponsored research agreement [Member]                      
Commitments and Contingencies (Textual)                      
Clinical trial cost for approval of food and drug administration             $ 13,200,000        
Medpace, Inc. [Member] | CRO Agreement [Member]                      
Commitments and Contingencies (Textual)                      
Total project estimated to cost                     $ 7,200,000
Research and development costs               $ 400,000 $ 900,000